{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-001849","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2024-01-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.651522+00:00","generated_at":"2026-06-07T00:24:34.792591+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AngioDynamics cuts FY24 revenue guidance to $320-325M; Q2 revenue $79.1M, Auryon sales up 12.9%","bullets":["FY24 revenue guidance lowered to $320M-$325M from $328M-$333M; adjusted EPS loss widens to ($0.35)-($0.42) from ($0.28)-($0.34).","Q2 FY24 pro forma revenue $79.1M, growth 2.7%; Med Tech +3.5%, Auryon sales $11.4M (+12.9% YoY).","PRESERVE (NanoKnife) and APEX AV (AlphaVac PE) studies fully enrolled; FDA submission for PE planned early 2024.","Cumulative Auryon sales exceeded $100M; CE Mark for Auryon and AlphaVac expected 1H 2024.","Full-year adjusted EPS profitability expected in FY27; manufacturing restructuring to fully outsourced model initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-001849","json":"https://secwatch.observer/filing/0001140361-24-001849.json","markdown":"https://secwatch.observer/filing/0001140361-24-001849.md","text":"https://secwatch.observer/filing/0001140361-24-001849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124001849/0001140361-24-001849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124001849/ef20018682_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:24:34.792591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}